I just returned from San Diego and the annual meeting of the American Society of Hematology, where Arcellx won the battle of ...

Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating reiterated by HC Wainwright in a note issued to ...

Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ...

With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off ...

The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma is getting extra spicy ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Arcellx Inc (ACLX – Research Report), with a price ...

Analysts have recently evaluated Arcellx and provided 12-month price targets. The average target is $107.71, accompanied by a ...

UBS analyst Ashwani Verma raised the firm’s price target on Arcellx (ACLX) to $114 from $106 and keeps a Buy rating on the shares. UBS believes ...

GSK, Gilead and Arcellx, Vertex and more present new data at the American Society of Hematology annual meeting just as sickle cell therapies Casgevy and Lyfgenia have a new outcomes-based payment ...

Arcellx (NASDAQ:ACLX – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports. They presently ...

--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable ...